Five cancer researchers receive 2021 New Discoveries Young Investigator Awards from BCAN

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Five researchers have received the 2021 New Discoveries Young Investigator Awards from the Bladder Cancer Advocacy Network. 

This is the first year BCAN has presented five awards. 

  • The 2021 New Discoveries Young Investigator Awards went to Brendan Guercio, a Hematology/Oncology fellow at Memorial Sloan Kettering Cancer Center, and Eugene Pietzak, assistant attending surgeon (urologic oncology) at Memorial Sloan Kettering Cancer Center. Guercio’s project title is “Associations of Patient Diet and Benefit from Immunotherapy in Urothelial Carcinoma” and Pietzak’s is titled “Defining the Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer.”

Each Young Investigator Award provides a $50,000 grant that supports one year of early career bladder cancer research. Since 2009, BCAN has awarded more than $5.5 million to promising scientists and research investigators across the country and these awards demonstrate that the important work to improve the understanding of bladder cancer and its impact on patients and families continues.

  • The two 2021 Palm Beach New Discoveries Young Investigator awardees are Filipe De Carvalho, urologic oncology fellow at Brigham and Women’s Hospital, and Benjamin Miron, medical oncology fellow at Fox Chase Cancer Center.  The title of Carvalho’s awarded project is “Clonal Architecture and Tumor Microenvironment of Cisplatin Resistant Localized Muscle Invasive Bladder Cancer” and Miron’s is “Relationship of Circulating Tumor DNA in Patients with Muscle Invasive Bladder Cancer to Pathologic Staging and Disease Prognosis.”
  • The 2021 New Discoveries Young Investigator Award for Patient Centered Research was awarded to Svetlana Avulova, urologic oncology fellow at Mayo Clinic. Avulova’s project is titled “Sexual Function in Women Undergoing Radical Cystectomy.”

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login